References
- Bhargava R, Chen B, Klimstra D, et al. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer 2006; 106: 1857–1862
- Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004; 5: 1621–1633
- Cunningham D, Humblet Y, Sienta S, et al. Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345
- Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279–286
- Shia J, Klimstra D, Li A, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005; 18: 1350–1356
- Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005; 12: 105–110
- dei Tos A, Ellis I. Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods?. Eur J Cancer 2005; 41: 1383–1392
- Sauer T, Guren M, Noren T, Dueland S. Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?. Histopathology 2005; 47: 560–564
- Spano J, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005; 16: 102–108
- Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17: 895–904
- Atkins D, Reiffen K, Tegtmeier C, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52: 893–901
- Chung K, Shia J, Kemeny N, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803–1810
- De Pas T, Putzu C, Pelosi G, et al. Target-treatment and patients' selection: Can we still neglect the timing of tissue collection?. J Clin Oncol 2005; 23: 6274–6275, (2005)
- Francoual M, Etienne-Grimaldi M, Formento J, et al. EGFR in colorectal cancer: more than a simple receptor?. Ann Oncol 2006; 17: 962–967
- Green, F, Page, D, Fleming, I, , et al. AJCC Cancer Staging Handbook6th ed.New YorkSpringer. 2002
- Kountourakis P, Pavlakis K, Psyrri A, et al. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J 2006; 12: 229–236, (2006)
- Scartozzi M, Bearzi I, Berardi R, et al. Epidermal Growth Factor Receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004; 22: 4720–4726